Clinical Research Center

Clinical Research Center

Todd Davies, PhD

Director of Research Development & Translation


To better coordinate and promote all graduate education at Marshall University Joan C. Edwards School of Medicine (JCESOM), we recently reorganized the Office of Research and Graduate Education. The office is located in Suite 301 in the Robert C. Byrd Biotechnology Science Center (BBSC). Along with the PhD, the MD/PhD, the Research MS and Medical Sciences MS in Biomedical Sciences, the new MS in Clinical and Translational Science degree is housed in this office. Second, a group consisting of current students, recent graduates, and faculty are redesigning the PhD curriculum, both modifying existing courses and adding new ones. These changes will better prepare our students to be more competitive in research that has become more translational and interdisciplinary.

As you can see, positive changes have taken place recently at the School of Medicine to significantly improve the education and training of our graduate students. Please feel free to stop by the Office of Research and Graduate Education to further explore these exciting new developments.

Guiding Principles

  • Long-term engagement

    Research Investigators are our long-term partners.  The MCRC seeks to build a lasting partnership with all of the researchers at the Joan C. Edwards School of Medicine

  • Mutual Benefit

    The MCRC understands the role and pressures of being a primary investigator.  It is our goal to enhance the environment, research and reputation of each of our partners.

  • Professionalism

    The Center staff will work together with humility, candor, and mutual respect for expertise and cultural differences when communicating with researchers and community members.

  • Shared Responsibility

    All partners have obligations towards the patients, the project, the community and each other.

  • Integrity

    All decisions and actions will be based on optimizing best-practices, maintaining data integrity, assuring safety, and upholding the highest standards of medical ethics and scientific quality.


We will be a world leader in community academic clinical research supporting medical innovation and care in Appalachia. To realize this vision, we will strive to:

  • develop a new standard for scholarship in clinical research.
  • nurture an environment of collaboration, creativity and professional development throughout the Marshall research community.
  • foster a goal-oriented and balanced approach to research.
  • advance effective strategic alliances.
  • provide access to cutting edge healthcare opportunities to the underserved community.

Clinical Trials

Below is a list of currently enrolling Clinical Trials at the Appalachian Clinical and Translational Science Institute (ACTSI). If you would like additional information about a specific trial, you can call the contact number provided and speak with a study coordinator.

Additional information about each trial can be obtained at by clicking on the descriptions below

Study ID PI Description Contact Information
NCT02329327 Cornell "A Study in Patients with Acute Major Bleeding to Evaluate the Ability of Andexanet Alfa to Revers the Anticoagulation Effect of Direct and Indirect Oral Anticoagulants (ANNEXA-4)" Robin Ashford: 304-691-1082
NCT01442194 Ferguson "Long-term, Prosepctive, Multi- national, parallel-cohort study Monitoring Safety in Patients with MS Newly Started with Fingolimod Once Daily or Treated with Another Approved Disease- Modifying Therapy" CLR1104 Linda Morgan: 304-691-1213
NCT02239120 Nolte "Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)" Melissa Marcum: 304-691-8560

Rebecca Smith: 304-691-1834
NCT02477618 Shah "A Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of SAGE547 Injection in the Treatment of Subjects with Super Refrac-tory Status Epilepticus" Robin Ashford: 304-691-1082

Doug Melton: 304-691-8618
NCT01797185 Ferguson "Open-label, safety study of SPARC1104 in Subjects with Spasticity due to MS" Linda Morgan: 304-691-1213
NCT02373904 Cheung "A Prospective, Multi-Center Study of the IlluminOSS Photodynamic Bone Sta-bilization System for the Treatment of Impending and Actual Pathological Fractures in the Humerus from Metastatic Bone Disease" Linda Morgan: 304-691-1213
NCT03114657 Neitch "A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of Crenezumab in Patients with Prodromal to Mild Alzheimer's Disease" Melissa Marcum: 304-691-8560
NCT02792218 Ferguson "A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study Comparing the Efficacy and Safety of Ofatumumab versus Teriflunomide in Patients with Relapsing Multiple Sclerosis" Linda Morgan: 304-691-1213

Doug Melton: 304-691-8618
NCT02878330 Lambros "A Phase 2B Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Mono-clonal Antibody with an Extended Half-Life Against Respiratory Synctial Virus, in Healthy Preterm Infants" Robin Ashford: 304-691-1082